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Objectives The purpose of this study was to investigate whether a relationship exists between an
acute reduction in resting left ventricular outﬂow tract (LVOT) gradient with balloon occlusion and
the ﬁnal invasive gradient response following alcohol septal ablation (ASA).
Background ASA is an alternative therapy to myectomy surgery to reduce the basal septal thick-
ness and decrease the resting and/or provocable LVOT gradient in patients with hypertrophic car-
diomyopathy. Patients have a variable gradient response to occlusion of the septal perforator artery
before ethanol infusion for ASA.
Methods From November 1998 to November 2008, 120 patients (mean age 60 years [range 16 to
87 years], 50% women) with hypertrophic cardiomyopathy underwent ASA at our institution. The
resting LVOT gradient (peak systolic left ventricle [LV] pressure – peak systolic aortic pressure) was
measured continuously during the ASA procedure. The time to signiﬁcant LVOT gradient decrease
(deﬁned as 50% decrease from baseline) was recorded following balloon occlusion of the domi-
nant septal perforator coronary artery, which was found to perfuse the basal septum based on con-
trast echocardiographic studies.
Results The mean baseline resting LVOT gradient was 86  43 mm Hg, and it decreased to 17 
1 mm Hg following ASA (80.2%). The mean time to signiﬁcant gradient reduction was 3.6  2
in (range 25 s to 11 min). The time to signiﬁcant LVOT gradient reduction strongly correlated with
he ﬁnal magnitude of gradient reduction following ASA (r  –0.81, p  0.001).
onclusions This study demonstrates a correlation between the time to signiﬁcant LVOT gradient
eduction following septal perforator balloon occlusion and the magnitude of ﬁnal gradient re-
ponse after ASA. (J Am Coll Cardiol Intv 2011;4:1030–4) © 2011 by the American College of
ardiology Foundation
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Ontario, Canada; and the †Division of Cardiology, Department of Medicine, Montreal Heart Institute, Montreal, Quebec,
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1031Hypertrophic cardiomyopathy (HCM) is a complex inher-
itable cardiac disease that affects approximately 1 in 500
individuals in the general population (1–4). A significant
proportion of patients with HCM have evidence of the
resting and/or provocable obstruction of the left ventricular
outflow tract (LVOT), which can result in severely limiting
symptoms, including dyspnea, angina, syncope, and sudden
death (5–8).
See page 1035
Some patients with significant LVOT gradients are unre-
sponsive to medical therapy and may require surgical myec-
tomy or alcohol septal ablation (ASA) to reduce basal septal
thickness and decrease their LVOT obstruction (9,10). At our
institution, we offer ASA as an alternative to myectomy
therapy in older patients with refractory symptoms who do not
have concomitant requirement for other surgical repair (e.g.,
mitral valve repair or replacement, or coronary artery bypass
graft surgery), and for patients who prefer this less invasive
approach. Although we determine whether the candidate
septal perforator artery perfuses the systolic anterior motion
(SAM)–septal contact point through the use of contrast
echocardiography during the procedure, we have noted that
balloon occlusion of the vessel can result in variable gradient
reduction before ethanol infusion.
The purpose of this study was to investigate whether a
relationship exists between the rate of acute reduction in
resting LVOT gradient with balloon occlusion of the
anatomically appropriate septal perforator and the final
gradient response following ASA.
Methods
From November 1998 to November 2008, 120 patients with
HCM underwent ASA at the Peter Munk Cardiac Centre,
University Health Network, Toronto, Ontario, Canada.
The procedure was offered to patients referred to our HCM
clinic with refractory symptoms despite being on maximally
tolerated medical therapy (beta-blockers, calcium-channel
blockers, and disopyramide) who were not candidates for
surgical myectomy, due to either comorbidities or patient
preference. All patients underwent comprehensive clinical,
echocardiographic, and coronary angiographic evaluation at
the Peter Munk Cardiac Centre. Coronary angiograms were
screened pre-ethanol ablation to ensure that there was at
least 1 anatomically appropriate septal perforator vessel of at
least 1.5-mm diameter that perfused the proximal interven-
tricular septum.
This study was approved by the University Health Net-
work Research Ethics Board.
Interventional procedure. The ethanol ablation procedure
ook place in our cardiac catheterization laboratory with the
ssistance of a dedicated HCM echocardiographic team. tust before procedure initiation, resting LVOT gradient and
eptal thickness measurements were taken in the catheter-
zation laboratory, at which point the patients had been off
edical therapy for 24 to 48 h. Resting LVOT gradients
ere measured using the maximum outflow tract flow
elocity using continuous-wave Doppler imaging and cal-
ulated using the modified Bernoulli equation.
After administration of conscious sedation, a right inter-
al jugular or right femoral venous sheath was placed for
nsertion of a temporary pacemaker wire into the right
entricular apex in all patients unless a permanent pace-
aker system was already present. The temporary pace-
aker was set at 60 beats/min during the procedure and was
ept in place for a minimum of 48 h after the procedure.
atients that become pacemaker-dependant at any point
ollowing the ablation procedure receive a dual-chamber
ermanent pacemaker implantation later during the admis-
ion. A 7-F femoral arterial sheath was inserted for the
uide catheter system, and a 5-F radial sheath was inserted
or pigtail catheter placement into the left ventricular cavity.
ontinuous invasive peak-to-
eak gradients were measured
cross the LVOT by comparing
he peak left ventricular and aor-
ic pressures.
Initial angiographic assess-
ent was performed to size the
eptal perforator and to localize
he vessel origin. The targeted
eptal branch was usually the
argest and most proximal septal
ranch arising from the left an-
erior descending artery (LAD).
n over-the-wire 8-mm balloon
ith a diameter matching that of the target branch was
dvanced into the septal branch so that the proximal marker
as placed just beyond the vessel ostium. Following balloon
nflation, 1 ml of echocardiographic contrast agent either
evovist (Berlex Canada Inc., Lachine, Quebec, Canada) or
efinity (Lantheus Medical Imaging Inc., North Billerica,
assachusetts) was injected into the index perforator vessel,
hile simultaneous echocardiographic assessment took
lace. The target vessel was considered suitable if there was
ppropriate contrast echocardiographic opacification of the
nterventricular septum at the site of the anterior mitral
eaflet SAM-septal contact point, and if there was not
pacification of other large nonseptal regions, such as the
nferior wall or papillary muscles. Further details on the
chocardiographic evaluation for ASA were previously pub-
ished (11,12).
If the target vessel appeared to be perfusing the appro-
riate septal region, a final check of the adequacy of balloon
eal was made by injection of dilute dye through the balloon
Abbreviations
and Acronyms
ASA  alcohol septal
ablation
HCM  hypertrophic
cardiomyopathy
LAD  left anterior
descending artery
LVOT  left ventricular
outflow tract
SAM  systolic anterior
motiono confirm the absence of spillage back into LAD. Before
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1032ethanol was infused through the over-the-wire balloon, we
left the balloon inflated in the septal perforator until the
LVOT gradient decreased by 50% from the baseline gradi-
ent, or the balloon was left inflated for 11 min without a
significant (50% from baseline) gradient response. Then,
95% Ethanol (0.1 ml per 1 mm of septal thickness, range 1.2
to 2.5 ml) was injected slowly through the over-the-wire
balloon over 8 min. The balloon was left inflated for an
additional 5 min following ethanol delivery to ensure that
there was no spillage back into the LAD following balloon
removal. Following balloon deflation and removal, invasive
and echocardiographic measurements were made. If an
adequate LVOT gradient reduction had not occurred,
further interrogation of other suitable perforator vessels was
performed, and additional ethanol was injected if appropri-
ate. All patients were monitored in the coronary care unit
following the procedure for at least 24 h. Creatine kinase
activity was monitored at 8-h intervals over the first 24 h
and daily thereafter for 3 days.
Statistical analysis. Data were expressed as mean  SD or as
requencies (%). The significance of the association between
ime to significant gradient reduction and final procedural
radient response was tested through the use of the Spearman
orrelation test. The software used for statistical analysis was
PSS (version 16.0, SPSS Inc., Chicago, Illinois).
esults
Baseline patient characteristics are depicted in Table 1. The
study population had a mean age of 60  15 (16 to 87)
years, with 50% women. Baseline symptoms in order of
frequency included dyspnea (90%), angina (50%), and pre-
syncope or syncope (38%). Medical therapy consisted of
disopyramide (82%), beta-blockers (71%), a combination of
these therapies (55%), and calcium-channel blockers (2%).
Coronary artery disease was present in 17.5% of patients.
Echocardiographic and hemodynamic variables are sum-
marized in Table 2. The average amount of ethanol injected
during the ablation was 1.8 0.5 ml (range 0.5 to 3.25 ml).
Peak post-procedural creatine kinase elevation was 1,106 
538 IU/l (range 239 to 3,252 IU/l).
Table 1. Baseline Patient Characteristics
Age, yrs 60 15
Female 50%
Symptoms
Dyspnea 90%
Angina 50%
Syncope/pre-syncope 38%
Medications
Beta-blocker 71%
Disopyramide 82%Values are mean SD or %.Delivery of ethanol for septal ablation occurred in 109
patients (91%). The 11 remaining patients (9%) did not have
ethanol injected for the following reasons: inappropriate ana-
tomical correlation between the septal artery and the SAM-
septal contact point by contrast echocardiography (6 patients);
technical failure with wiring or balloon advancement (2 pa-
tients); left main and LAD coronary dissection (1 patient); and
no gradient response with balloon inflation (1 patient).
In patients who received ethanol injection, the mean max-
imum resting LVOT gradient was 86  43 mm Hg, and it
ecreased to 17  11 mm Hg following ASA (80.2%)
(Table 2). Data on time to significant LVOT gradient reduc-
tion were available for 97 patients (89%). Time required for
balloon inflation to result in a significant LVOT gradient
decrease ranged from 25 s to 11 min (mean 3.6 2 min). The
time to significant decrease in resting LVOT gradient follow-
ing balloon occlusion was highly correlated with the overall
magnitude of final LVOT gradient reduction following etha-
nol ablation (r  0.81; p  0.001) (Fig. 1).
iscussion
ASA is a safe procedure to treat appropriately selected
patients with HCM whose symptoms are refractory to
optimal medical therapy. In this report, we describe that a
novel measurement (the length of time to significant LVOT
gradient reduction) following balloon occlusion in patients
undergoing ASA predicts final resting invasive LVOT
gradient reduction. In this cohort, there exists an inverse
relationship between the time to significant gradient reduc-
tion and final gradient response.
Sigwart et al. (13) first demonstrated in 1982 that brief
occlusion of the septal artery with a balloon catheter causes
transient reductions in the outflow pressure gradient. Before
contrast echocardiographic techniques were widely used and
available, balloon occlusion alone was the standard tech-
nique to evaluate the anatomical suitability of the target
septal branch (14,15). The procedure has undergone signif-
icant technical refinements; the most notable of which is the
introduction of myocardial contrast echocardiographic lo-
Table 2. Echocardiographic and Hemodynamic Parameters
Basal septal wall thickness, mm 20 4
Left atrial size, mm 47 6
Resting echo gradient, mm Hg 74.4 39.6
LV end-systolic dimension, mm 24 4
LV end-diastolic dimension, mm 43 5
Mean gradient pre-ASA, mm Hg 86 43
Mean gradient post-ASA, mm Hg 17 11
Mean time to signiﬁcant decrease in resting gradient with
balloon inﬂation, min
3.6 2.0
Values are meanSD.
ASA alcohol septal ablation; LV left ventricular.calization of the target area.
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1033The use of myocardial contrast echocardiography to
evaluate the area at risk is considered a key aspect for the
localization of the ablation, which ideally should be centered
at the point of contact with the anterior mitral leaflet
(16,17). Echocardiographic evaluation of the change in
myocardial mechanics and the septal strain after balloon
occlusion and ASA was found to have an important role in
the understanding of the time course of the gradient
reduction (18). Moreover, the reduction in septal strain after
ASA can serve as an early determinant for the outcome.
Immediate decrease in ventricular septal strain after ablation
correlates to the decrease in LVOT gradient long term (19).
This suggests that the lower the septal strain, the better the
long-term gradient reduction.
In this study, we have further refined this technique by
demonstrating that patients who get a rapid gradient re-
sponse following balloon occlusion are more likely to have a
more significant final resting reduction. The fact that
gradient reduction happens more rapidly in those patients
with a larger post-procedural response may reflect more
precise anatomical ablation of the appropriate SAM-septal
contact point. Thus, although contrast echo is able to
reliably identify patients who are likely to respond, this
additional measurement predicted which patients would
have the best post-procedural gradient outcomes. Impor-
tantly, patients who took a very long time to manifest a
gradient reduction did not have a large magnitude of final
LVOT gradient response. This raises a question regarding
the efficacy of ethanol delivery to patients who have little or
no significant responsiveness after a significant amount of
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Figure 1. Relationship Between Time of Balloon Inflation and Final Invasive
The graph illustrates the correlation between the time interval (min) of balloo
age magnitude of ﬁnal gradient response (x axis) using Spearman correlationtime has passed following balloon inflation.Study limitations. Several limitations must be considered in
his report. First, this report has the limitations inherent to the
nalysis of retrospective nonrandomized data. We must also
cknowledge the small sample size in this report. Some
atients did not have data on time to gradient reduction
ollowing balloon inflation, which may have influenced the
nal results.
onclusions
Through modern techniques, focal ASA is an attractive
alternative to myectomy surgery in older patients with
significant comorbidities and a favorable coronary anatomy.
This study demonstrates a significant correlation between
septal perforator balloon occlusion and the magnitude of
final gradient response during ASA. Our findings suggest
that patients who have a rapid gradient reduction during
balloon occlusion are more likely to have a larger final
gradient response following ethanol ablation.
Reprint requests and correspondence: Dr. Christopher Over-
gaard, Interventional Cardiology, University Health Network, 6
Eaton North Room 232, Toronto General Hospital, Toronto,
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